immune-normalizers
(2)
Normunity
Normunity is a clinical-stage biotech building a new class of cancer drugs it calls 'immune normalizers' - antibodies and T cell engagers that target previously hidden mechanisms tumors use to evade the immune system. Founded on the science of Yale immunologist Lieping Chen and led by drug-development veteran Rachel Humphrey, the company runs research at Yale's West Campus in West Haven, Connecticut, and dosed its first patient in 2025.
Rachel Humphrey
Rachel W. Humphrey, MD, is the founding CEO of Normunity, a Boston and New Haven biotech building a new class of cancer drugs called immune normalizers, drugs designed to free the immune system to attack tumors it normally ignores. Before Normunity she helped bring three blockbuster cancer therapies to patients: Yervoy at Bristol Myers Squibb, Imfinzi at AstraZeneca, and Nexavar at Bayer. She partnered with Yale immunology pioneer Lieping Chen to translate his discoveries at the cancer-immune interface into medicines, raising $65M to launch in 2022 and a $75M Series B in January 2025 to push lead program NRM-823 into the clinic.